Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Florbetaben PET amyloid burden and cognition after DBS in Parkinson's disease
2014-001014-25Phase 4Active
- Sponsor
- Fundació de Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi i Sunyer
- Start
- Jul 2016
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of flutemetamol in Parkinson's disease (PD), sponsored by Fundació de Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi i Sunyer. Primary endpoint: Incidence of adverse events after single-dose florbetaben PET. Started Jul 2016; status: active.
02
Drugs
flutemetamol
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2014-001014-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001014-25.